PHILADELPHIA, PA / ACCESS Newswire / February 21, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives."
On February 21, 2025, bluebird bio announced an agreement to be acquired in a deal bluebird bio said is a "transaction [that] is the only viable solution to generate value for stockholders."
On this news, bluebird bio’s stock was down more than 38% pre-market on February 21, 2025.
INVESTORS OF BLUEBIRD BIO STOCK CAN SEND US A MESSAGE OR COMPLETE OUR SECURITIES QUESTIONNAIRE TO CONTACT AN ATTORNEY TO DISCUSS THE INVESTIGATION AND POTENTIAL LEGAL CLAIMS.
Investors of bluebird bio interested in additional information about the merger investigation can also contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, or info@kehoelawfirm.com for a free, no-obligation legal evaluation.
Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm, P.C. have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.
This press release may constitute attorney advertising.
SOURCE: Kehoe Law Firm, P.C.
View the original press release on ACCESS Newswire
COMTEX_462994590/2457/2025-02-21T09:46:37